In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeiGene Ltd.

www.beigene.com

Latest From BeiGene Ltd.

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.

Financing Innovation

Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue

Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.

Research and Development Strategies Companies

Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Deals Business Strategies

J.P. Morgan Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.

Business Strategies Launches
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • BeiGene (Beijing) Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • BeiGene Ltd.
  • Senior Management
  • John V Oyler, CEO
    Howard Liang, PhD, CFO & Chief Strategy Officer
    Guillaume Vignon, PhD, SVP, Bus. Dev.
  • Contact Info
  • BeiGene Ltd.
    Phone: 10 851 48500
    No. 30 Science Park Rd. Zhong-Guan-Cun
    Life Science Pk
    Changping District, 102206
    China
UsernamePublicRestriction

Register